[{"Assets_0_Q3_USD":390972000.0,"EarningsPerShareBasic_1_Q3_USD":0.22,"EarningsPerShareBasic_3_Q3_USD":0.71,"EarningsPerShareDiluted_1_Q3_USD":0.21,"EarningsPerShareDiluted_3_Q3_USD":0.67,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":93890000.0,"StockholdersEquity_0_Q3_USD":-222961000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":119796000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":120120000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":106841000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":107236000.0,"Ticker":"INVA","CIK":"1080014","name":"INNOVIVA, INC.","OfficialName":"Innoviva Inc. Common Stock","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1257937389.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20171103"}]